Sheba Medical Center Initiates Ivermectin Study in Pursuit to Investigate Economic & Available COVID-19 Therapy

Jun 13, 2020 | Coronavirus, COVID-19, Israel, Leading Sites, SARS-CoV-2, Sheba Medical Center, Site Success, Site Watch, Tropical Medicine

Sheba Medical Center Initiates Ivermectin Study in Pursuit to Investigate Economic & Available COVID-19 Therapy

The top hospital in Israel, and the 9th worldwide, launched an Ivermectin clinical trial targeting COVID-19 patients. The elite Israeli center led by Professor Eli Schwartz seeks to show the world the potential for this economic and available FDA-approved drug.

A Heavy Hitter

Professor Schwartz, a world-renowned expert in tropical diseases and travel medicine, has undoubtedly has been exposed to the use of Ivermectin in tropical locations. Dr. Schwartz heads the Center for Travel Medicine and Tropical Diseases at Sheba Medical Center and also serves as a Professor at the Sackler Faculty of Medicine in Tel Aviv.

The Study

Ivermectin is known as a broad-spectrum anti-parasitic agent but also exhibits anti-viral activities, which is why the drug has been embraced around the world as a possible therapy targeting SARS-CoV-2. The Sheba Medical Center has been observing the unfolding studies and has made the strategic move to conduct an efficient study, which commenced in May and runs until October 2020.

The randomized, parallel assignment, double-blind quadruple mask study will include 100 patients. Dr. Schwartz and the team have established viral clearance within six days post-intervention, which, if the study meets this objective, would start to establish the superiority over remdesivir. Other measures include viral shedding duration time and symptoms clearing time.

Patients 18 years or older with molecular confirmation of COVID-19 will be eligible for a period no longer than 72 hours post-exposure. Those that are pregnant or breastfeeding, have a severe infection, under 40kg or over 100kg, not able to consume oral medication or have known allergies, can’t participate. Neither can a patient that is participating in another study.

The Center

Sheba Medical Center is the number one ranked hospital in Israel and ninth worldwide, according to a 2020 Newsweek ranking. Located in Tel HaShomer of Ramat Gan in Tel Aviv, the hospital was established back in 1948 as Israel’s first military hospital. Situated east of Tel Aviv, the 150-acre campus operates 120 departments and clinics with 1,700 beds and over 1,400 physicians, 2,600 nurses, and 3,300 healthcare workers. The center receives over a million patient visits per year, including 200,000 emergency visits. 

The Sheba Center of Geographic Medicine and Tropical Disease is recognized as a top leading medical facility and the largest of its kind in Israel. Its physicians are all certified in travel medicine, with ISTM Certificates of Knowledge. (CTH).

Sheba Medical Center Medical Research is known to be at the forefront of clinical research in Israel and beyond.

Lead Research/Investigator

Professor Eli Schwartz, MD, Director of the Center for Geographic Medicine at Sheba Medical Center

Call to ActionTrialSite News is quite bullish about the momentum Ivermectin has in investigations, looking into its efficacy in regards to COVID-19. TrialSite News tracks these studies, so if you want updates, sign up for the daily newsletter.

1 Comment

  1. Dr. Shahabuddin Mahmud

    What was the dose and duration of Ivermectin in this study ?

Pin It on Pinterest